Polycystic Kidney Disease – Landscape & Forecast – Disease Landscape & Forecast
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly, in the early stages, the disease is often asymptomatic and detectable only through diagnostic imaging of the kidney to reveal cysts. The launch of Otsuka’s Jynarque / Jinarc / Samsca (tolvaptan) introduced the first disease-specific therapy for ADPKD. Several more therapies for ADPKD are in clinical trials, including Reata Pharmaceutical’s bardoxolone methyl, Galapagos’s GLPG2737, Kadmon’s tesevatinib, and Xortx Therapeutics’ oxypurinol. Some of these therapies are expected to fulfill current unmet needs in the treatment of ADPKD.
Questions answered
- What do key opinion leaders think about the emerging therapies bardoxolone methyl, GLPG2737, tesevatinib, and oxypurinol? How will emerging therapies differentiate themselves in an increasingly crowded market?
- How will the anticipated genericization of Otsuka’s Jynarque / Jinarc / Samsca affect the uptake of branded and emerging therapies?
- What effect have the discontinuations of Sanofi / Genzyme’s venglustat, Regulus Therapeutics’ RGLS-4326, and Palladio Bioscience’s lixivaptan had on the ADPKD therapy market?
- What are the key unmet needs in ADPKD, and which therapies likely to fulfill them?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement:
Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Polycystic Kidney Disease - Landscape & Forecast - Disease Landscape & Forecast
- Key updates
- Key findings
- Market outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for ADPKD?
- What factors are constraining the market for ADPKD?
- Annual sales for total ADPKD by progression rate segments: 2021-2031
- Annual sales of drug classes for total ADPKD: 2021-2031
- Annual patient share of key drug classes for ADPKD rapid progressors or at risk of rapid progression forms
- Annual patient share of key drug classes for ADPKD intermediate/ slow progression forms
- Drug-type-specific trends
- Forecast
- Etiology and pathophysiology
- Epidemiology
- Current treatment
- Unmet need overview
- Drug pipeline
- Emerging therapies
- Access & reimbursement overview
- Methodology
- Appendix
Laia Martínez-Carreres, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematological Disorders. Dr. Martinez-Carreres has authored reports on polycystic kidney disease, venous thromboembolism, and atrial fibrillation. Prior to joining Clarivate, she was a clinical research project manager at Parc Taulí Hospital (Spain). She holds a Ph.D. in biomedical sciences from the University of Lausanne, where she studied the role of the cell cycle-related protein CDK4 in metabolism in the laboratory of Professor Lluis Fajas. She also holds a master’s degree in translational medicine and a bachelor’s degree in biomedical sciences, both from the University of Barcelona. Dr. Martínez-Carreres also trained as a data analyst at EADA Business School in Spain.